Dexclorfeniramina

Quick links

Choose a section

Quick links to important sections

Advertisements

Dexclorfeniramina

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Dexclorfeniramina

Property Description
Active Ingredient Dexchlorpheniramine maleate
Form Tablets, Syrup, Oral solution, Extended-release formulations
Pharmacological Class First-generation H1-receptor antagonist
General Purpose Counteracting systemic allergic responses
Origin Synthetic, S-enantiomer

What Type of Medicine is Dexchlorpheniramine?

Dexchlorpheniramine is classified as a first-generation H1-receptor antagonist, a synthetic compound belonging to the alkylamine derivative class, and is clinically recognized for its role in modulating the body's response to hypersensitivity. The active substance is Dexchlorpheniramine maleate, which is the pharmacologically potent S-enantiomer derived from the racemic Chlorpheniramine substance, a point of distinction in its chemical profile. This chemical isolation differentiates the agent within its class, distinguishing it as a highly specific inhibitor of histamine action. Its mechanism is both centrally and peripherally active, a key feature that positions it among traditional antihistamines.

Composition and Available Forms of Dexchlorpheniramine

The composition consistently features the stable salt form, Dexchlorpheniramine maleate, prepared with specific solid excipients or an aqueous or syrup base for administration. The medicine is primarily delivered via the oral route and is produced in several standard pharmaceutical preparations to optimize delivery, including immediate-release tablets, liquid forms such as syrup and oral solution, and specialized extended-release formulations. This range of forms ensures the potent S-enantiomer can be effectively delivered regardless of the required therapeutic duration or patient group.

How Does Dexchlorpheniramine Generally Help?

The general purpose of Dexchlorpheniramine is to mitigate systemic reactions caused by the pathological release of histamine. Its function is achieved through Histamine H1 receptor competitive inhibition, meaning it blocks histamine from binding to its target sites on cell surfaces. By preventing this chemical messenger from initiating its effect, the medicine helps suppress the undesirable physiological signals of the allergic response. This mechanism acts to counteract the internal inflammatory cascade. The conclusion drawn is that this medicine helps counteract the undesirable biological processes associated with allergic reactions.

Advertisements

What side effects are possible with Dexclorfeniramina?

Possible Side Effects and Safety Information

The safety profile of Dexclorfeniramina is established through regulatory classification of adverse reactions by frequency and organ system.

Common and System-Related Reactions

The most commonly documented side effects are typically related to the Nervous System and are often more noticeable at the beginning of treatment. These reactions include somnolence (drowsiness) and sedation, dizziness, and disturbed coordination. Other frequent occurrences are associated with anticholinergic effects, such as dry mouth and throat, blurred vision, and difficulty with urination (urinary retention), which may be more likely in older adults.

System-Organ Class Examples of Documented Reactions
Nervous System Disorders Sedation, somnolence, vertigo, confusion, restlessness, tremor
General Disorders Dryness of mouth, nose, and throat (anticholinergic effects), fatigue, excessive perspiration
Gastrointestinal Disorders Nausea, vomiting, constipation, epigastric distress

Serious Adverse Reactions

Official regulatory sources note the potential for rare but serious adverse reactions requiring prompt medical attention. These include severe generalized hypersensitivity events, such as anaphylactic shock and angioedema (swelling of the face, tongue, or throat). Additionally, clinically significant effects on the Blood and Lymphatic System have been documented, including hemolytic anemia, thrombocytopenia, and agranulocytosis.

Population-Specific Safety Considerations and Restrictions

Regulatory documents emphasize specific safety cautions for certain patient groups. The medicine is contraindicated in newborns and premature infants due to high sensitivity to antihistamine effects. Older adults may experience increased susceptibility to confusion, dizziness, and anticholinergic effects like constipation and urinary retention. Use during the third trimester of pregnancy is contraindicated. Furthermore, the co-administration of this medicine with Monoamine Oxidase Inhibitors (MAOIs) or within two weeks of stopping MAOIs is strictly contraindicated due to the risk of severe hypotension.

Advertisements

Overdose and Emergency Response

The official regulatory documents classify Dexchlorpheniramine overdose as having the potential for severe and life-threatening toxicity. Documented overdose presentations include signs of both central nervous system (CNS) and anticholinergic toxicity. Symptoms may manifest as extreme sleepiness, confusion, agitation, and hallucinations, alongside physical signs like a rapid heartbeat, dilated pupils, dry mouth, flushing, and inability to urinate.

Overdose carries a significant risk of severe outcomes, including seizures, coma, fatal respiratory depression, and serious cardiac rhythm disturbances (cardiac arrhythmia) marked by QRS/QT interval prolongation. Immediate medical attention is required upon any suspected overdose; the regulatory guidance explicitly mandates contacting the Poison Control Center or local emergency services right away.

Population-specific notes confirm that children may paradoxically exhibit excitement and have an increased risk of convulsions. The elderly face greater susceptibility to confusion and heightened anticholinergic toxicity. As no specific antidote is documented, management is purely symptomatic and supportive. Procedures involve constant cardiac monitoring, vital signs assessment, and potential administration of activated charcoal or medicine to control specific symptoms like seizures or severe agitation.

Advertisements

Therapeutic Uses of Dexclorfeniramina

Dexclorfeniramina is a medication used to alleviate symptoms associated with allergic conditions and the common cold. It is utilized to provide temporary relief from a number of reactions involving the respiratory system and skin.


Quick Facts: Therapeutic Uses

  • Provides relief for runny nose and sneezing.
  • Helps manage itching of the eyes, nose, throat, or skin.
  • Contributes to the control of watery eyes.
  • Assists in the management of hives (urticaria) and certain rashes.

The primary benefit of this treatment is the reduction of discomfort caused by the body's reaction to allergens. Dexclorfeniramina is a pharmacologically active component utilized for these applications.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility and Contraindications

Dexchlorpheniramine eligibility is defined by absolute contraindications and mandatory caution for specific populations and comorbidities documented in regulatory labels.

Absolute Contraindications

Use is strictly prohibited for newborns and premature infants, as well as breastfeeding mothers. Patients with known hypersensitivity to the active substance or other related antihistamines must not use this medicine. The drug is contraindicated for those with narrow-angle glaucoma, urinary retention due to obstruction, or acute asthma attacks and other lower respiratory tract symptoms. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI therapy is also prohibited.

Age and Condition Restrictions

The medicine is generally contraindicated for use in children under 2 years of age. Regulatory guidance mandates caution for use in older adults due to increased susceptibility to side effects. Patients with hepatic or renal impairment, hypertension, hyperthyroidism, or existing cardiovascular disease require cautious use due to the risk of accumulation or exacerbation of their condition. Use during the third trimester of pregnancy is restricted due to potential adverse effects on the neonate.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Dexchlorpheniramine, focusing strictly on information derived from governmental regulatory sources.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This prohibition extends to the use of Dexchlorpheniramine for 14 days after stopping MAOI therapy. Regulatory documents state that MAOIs can prolong and intensify the anticholinergic and sedative effects of the antihistamine.

Pharmacodynamic Interactions

Interacting Agent Category Official Interaction Outcome
Central Nervous System (CNS) Depressants (e.g., opioids, sedatives, tranquilizers) Results in an additive CNS depressant effect, enhancing drowsiness and impairment.
Anticholinergic Drugs May lead to additive adverse effects related to cholinergic blockade, such as blurred vision or dry mouth.

Substance and Population Considerations

Regulatory labeling specifically documents that Alcohol (ethanol) can enhance the CNS depressant effect of the medicine and should be avoided. Furthermore, interaction risks, particularly those resulting in enhanced sedation and dizziness from additive pharmacodynamic effects, are officially noted as being more likely to occur in the elderly population (aged 60 or older), requiring specific caution when assessing concurrent therapy.

Advertisements

Mechanism of Action

How Dexclorfeniramina Works


Modulating H1 Receptor Signaling

This domain addresses the drug’s primary biological target: acting as an antagonist to block the histamine H1 receptor found in peripheral tissues. By binding to this receptor, the drug suppresses the normal activation cascade triggered by the natural mediator, histamine, which modifies early molecular steps that result in systemic physiological changes.


Influencing Central Nervous System Activity

This domain covers the drug's mechanism within the central nervous system (CNS), which affects systems where specific transmitters dominate. The drug's ability to cross into the brain allows it to engage central H1 receptors, leading to the modulation of neural signaling associated with alertness. This action contributes to a slowing of central nervous activity, resulting in modulation of signaling within these pathways.

Advertisements

Dosage and Administration Information

Dexchlorpheniramine is administered exclusively via the oral route, available in immediate-release tablets, syrups, and specialized extended-release formulations. Proper usage is defined by adherence to specific dosing guidelines and procedural instructions.

Official Dosing Regimens

Age Group Immediate-Release Dose (Standard) Frequency / Maximum
Adults (≥ 12 years) 2 mg Every 4 to 6 hours, not to exceed 12 mg/24 hours.
Children (6 to 11 years) 1 mg Every 4 to 6 hours (Maximum 6 mg/24 hours).
Children (2 to 5 years) 0.5 mg Every 4 to 6 hours (Maximum 3 mg/24 hours).

For extended-release forms, the standard adult dose is typically 4 mg to 6 mg per administration, often taken every 8 to 10 hours or at bedtime.

Administration Requirements

  • Timing: The medicine can be taken with or without food.
  • Liquids: Liquid forms must be measured with an accurate milliliter measuring device (not a household spoon) to ensure dose precision.
  • Extended-Release Forms: These tablets or capsules must be swallowed whole and must not be crushed, chewed, or broken to maintain the integrity of their timed-release mechanism.
  • Missed Dose: If a dose is missed, the standard protocol is to skip the missed dose if the next scheduled dose is near, and not take a double dose to compensate.
Advertisements

Recent Clinical Evidence

Evidence Landscape for Allergic Rhinitis (Hay Fever) Studies

Dexclorfeniramina was studied for symptoms of allergic rhinitis (including seasonal hay fever and year-round allergies) primarily utilizing Randomized Controlled Trials (RCTs) and controlled studies. These studies explored how symptoms changed over time when the agent was compared to an inactive substance or active comparators. The research examined patient-reported outcomes related to nasal symptoms (sneezing, running nose) and ocular symptoms (eye itching, tearing). The agent was evaluated in study populations that mainly included Adults and Adolescents, and the evidence is derived from a long history of use documented in clinical evaluations.


Evidence Landscape for Allergic Skin Manifestations (Hives and Itching)

Research relevant in studies assessing short-term or episodic symptom patterns for conditions such as hives (urticaria) and general itching (pruritus) is often drawn from Regulatory Summaries. The research examined outcomes related to physical discomfort, specifically monitoring the severity of itching and the presence of wheals. The compiled evidence for this indication is a part of the broader evidence landscape for first-generation allergy treatments, though comparative evidence against contemporary standards of care is limited.


Evidence Landscape for Topical Use (Skin Irritation) Research

Research exploring short-term symptom changes in skin irritation involves specific trial types, including Short-Term Non-inferiority Clinical Trials and Open-Label Comparative Studies. These studies were conducted during periods of increased symptom activity in subjects with solar erythema (sunburn). Outcomes linked to inflammatory or irritative states were monitored, including the intensity of itching, redness, and burning sensation. Follow-up durations were typically limited to about seven days.


Research Gaps and Uncertainty

The majority of formal, controlled research utilized limited follow-up durations, meaning long-term effects are not fully established regarding durability of symptom control. Data for certain groups, particularly medically complex patient subgroups, remain insufficient. Research has examined the agent in children and older adult populations, but dedicated studies focusing solely on efficacy in high-risk subgroups are uncertain. The evidence quality varies across studies, with many core indications relying on older research or established use.

Key Studies & References

  1. NIH MedlinePlus Drug Information: Chlorpheniramine
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dexclorfeniramina (FAQ)

Q: How quickly can a person generally expect Dexclorfeniramina to start working?

A: Initial effects of the medicine are typically observed relatively quickly, starting within 30 to 60 minutes after taking a dose. This range is generally consistent with the drug’s pharmacological profile.

Q: How long does the effect of Dexclorfeniramina typically last in the body?

A: For the immediate-release form of Dexclorfeniramina, the duration of the effect is generally reported to be approximately four to eight hours. This duration is consistent with the drug’s properties as described in regulatory documents.

Q: What is the difference between Dexclorfeniramina and other common antihistamines?

A: Dexclorfeniramina is classified as a 'first-generation' antihistamine. The key distinguishing factor is its ability to cross into the central nervous system (CNS), which contributes to its potential to cause sedation or a slowing of central nervous activity. Newer antihistamines are generally described as having primary action in the peripheral body.

Q: Is it true that Dexclorfeniramina is the more active part of Chlorpheniramine?

A: Yes, official chemical and pharmacological information confirms that Dexclorfeniramina is the 'S-enantiomer,' which is the pharmacologically active component isolated from the racemic mixture known as Chlorpheniramine.

Q: What does the term 'first-generation antihistamine' imply about Dexclorfeniramina?

A: This classification is used because the medicine is known to have sedative properties, due to its effect on the central nervous system. Regulatory documents list common side effects associated with this, such as drowsiness and sedation.

Q: Does Dexclorfeniramina have any anticholinergic effects, and what does that mean?

A: Yes, the drug is documented to have anticholinergic effects. This term is related to the drug’s potential to cause 'drying' side effects. Documented reactions include dry mouth, blurred vision, and difficulty with urination.

Q: Does the drug's effect change if it's taken on an empty stomach versus with food?

A: According to official administration requirements, the medicine can be taken either with food or without food. This instruction suggests that the effectiveness of the medicine is not critically dependent on meal timing.

Q: Is Dexclorfeniramina the same drug as Chlorphenamine or Chlorpheniramine?

A: No, the official name is distinct, though the substances are closely related. Dexclorfeniramina is the single, more potent active component, known as the S-enantiomer, which is chemically derived from the racemic mixture called Chlorpheniramine or Chlorphenamine.

Q: Is Dexclorfeniramina an over-the-counter (OTC) drug or is it prescription-only in most places?

A: The regulatory status of the drug varies based on the specific formulation and country. Some single-ingredient products or formulations are regulated as prescription drugs, while some combination products containing the drug may be available over-the-counter.

Q: Are there any specific foods or drinks that should be avoided while using this medicine?

A: Official labeling explicitly documents that alcohol can enhance the Central Nervous System (CNS) depressant effect of the medicine. No specific warnings for foods are typically listed in the required interaction sections.

Q: Can Dexclorfeniramina be used to help with sleep due to its sedative effects?

A: The primary purpose listed in official labeling is the treatment of allergy symptoms. Regulatory documents include a specific warning stating that the product should not be used for the sole purpose of making a child sleepy.

Q: Is it possible to become dependent on Dexclorfeniramina if used for a long time?

A: While long-term effects are not fully established in studies, warnings regarding habit formation or drug dependence are not typically included in the official product information for this medicine.

Q: What kind of research has been done on the long-term use of Dexclorfeniramina?

A: Regulatory documents mention that the majority of formal, controlled research utilized limited follow-up durations. Therefore, long-term effects regarding the durability of symptom control are generally not fully established in the existing clinical evidence.

Q: Does Dexclorfeniramina interact with common pain relievers like paracetamol or ibuprofen?

A: Official interaction sections do not list specific contraindications or warnings for common non-opioid pain relievers such as paracetamol (acetaminophen) or ibuprofen. Interactions primarily focus on CNS depressants and MAOIs.

Q: Why is Dexclorfeniramina sometimes combined with other ingredients in cold medicines?

A: Dexclorfeniramina acts as an antihistamine to help mitigate allergy-related symptoms such as watery eyes and sneezing. It is combined with other agents, like cough suppressants or nasal decongestants, to create comprehensive formulas for treating the multiple symptoms of colds and flu.

Q: Is Dexclorfeniramina known to cause heart palpitations or changes in heart rhythm?

A: Adverse effects on the heart, such as fast heart rate (tachycardia) and palpitations, have been documented, although they are generally rare. These effects are generally noted as being associated with overdosage or in individuals with pre-existing cardiovascular conditions.

Q: Can Dexclorfeniramina affect mental clarity or ability to focus?

A: Official information indicates this medicine may affect mental function. Documented reactions include confusion and dizziness, and caution is advised because the drug has the potential to impair mental alertness, coordination, and clear vision.

Q: Does Dexclorfeniramina interact with herbal supplements or vitamins?

A: Authoritative drug interaction databases note that certain herbal supplements, particularly those with known sedative properties, may enhance the central nervous system depressant effects of the medicine.

Q: What should be done if a potential side effect from Dexclorfeniramina is experienced?

A: For side effects that are mild or bothersome, guidance from a healthcare professional may be sought. For rare but severe adverse reactions, such as symptoms of a serious allergic reaction, regulatory documents instruct users to seek immediate medical attention.

Q: Is Dexclorfeniramina known to cause weight changes (gain or loss)?

A: In addition to common side effects, drug safety databases have documented increased appetite and weight gain as less common or rare adverse reactions associated with the use of this medicine.

Q: What is the typical time frame for the drug to clear out of a person's system?

A: The half-life of Dexclorfeniramina, which is the time needed for the body to eliminate half of the drug, is generally stated in regulatory documents to be between 8 and 12 hours. The medicine is fully cleared from the system after several half-lives.

Q: Can people with kidney or liver problems use Dexclorfeniramina?

A: The official eligibility criteria state that caution is needed for use in patients with hepatic (liver) or renal (kidney) impairment. This caution is due to the potential risk of the drug accumulating in the body and increasing the chance of side effects.

Q: Are there any official restrictions on the maximum length of time this drug should be used?

A: For products regulated for over-the-counter use, official guidance typically advises consulting a doctor if symptoms persist or do not improve within seven days of beginning the medicine.

Q: Is there a risk of withdrawal symptoms after stopping Dexclorfeniramina?

A: Advisory drug documents note that discontinuing a sedating antihistamine may, in some cases, result in mild anticholinergic discontinuation symptoms, such as anxiety or dizziness.

Q: Is it possible for Dexclorfeniramina to affect blood pressure?

A: Official documents list pre-existing high blood pressure as a condition where use requires caution. Changes in blood pressure, including both increases and decreases, have been reported as uncommon reactions, mostly in the context of overdosage.

Q: Are there different brand names for the drug Dexclorfeniramina?

A: Yes, the active ingredient Dexclorfeniramina maleate is marketed globally under various brand names, which may include Polaramine and Ryclora, depending on the country and specific formulation.

Q: What is the official information regarding the use of Dexclorfeniramina in individuals with asthma?

A: Regulatory documents state that the drug should not be used to treat lower respiratory tract symptoms. Its use is officially prohibited during an acute asthma attack.

Q: How does the mechanism of action of Dexclorfeniramina compare to second-generation antihistamines?

A: The mechanism of Dexclorfeniramina involves blocking H1 receptors both peripherally and centrally. Newer, second-generation antihistamines are generally described as targeting H1 receptors primarily in the peripheral body, which results in less central activity.

Q: Do studies support the use of Dexclorfeniramina for chronic, non-allergic conditions?

A: The approved indications and available research evidence summarized in regulatory documents are specifically focused on mitigating symptoms related to various allergic conditions. Consequently, official indications and supporting research are not listed for chronic, non-allergic conditions.

Advertisements

How should Dexclorfeniramina be stored and disposed of?

Storage and Disposal Guidelines

Official regulatory documents require that Dexchlorpheniramine maleate preparations be stored under strict conditions to maintain product stability and ensure household safety.

Storage Conditions

Requirement Details
Temperature Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F).
Protection The medicine must be protected from light and should not be frozen.
Container Liquid forms should be dispensed in a tight, light-resistant container with a child-resistant closure.
Child Safety The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product must be disposed of according to local regulations. The medicine should not be flushed down sinks or toilets. If a drug take-back program is unavailable, it is recommended to mix the product with an undesirable substance, such as coffee grounds, seal it in a plastic bag, and then discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexclorfeniramina found in:

A-Z Index: